EGFR and non-small cell lung carcinoma: Along the same lines, a more limited metastatic spread with less extrapulmonary metastatic sites, as well as a better ECOG PS for secondary (relapsed) vs. de novo metastatic tumors have also been noted by other investigators, who analyzed unselected NSCLC patients regardless of EGFR mutation status (24, 25).